Full-Length GPC3 Detection for Hepatocellular Carcinoma Recurrence Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the recurrence of hepatocellular carcinoma using GPC3 biomarkers are inadequate, as they fail to accurately distinguish between recurrence and non-recurrence groups and often detect GPC3 in healthy individuals, leading to insufficient detection accuracy.
Innovation Solution
A method involving the use of a detection system that measures full-length GPC3 in blood samples using both N-terminal and C-terminal peptide-recognizing monoclonal antibodies, allowing for the determination of recurrence risk based on peptide concentration above or below a predetermined threshold.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection systems using N-terminal or C-terminal peptide recognition antibodies are used, then GPC3 can be detected in hepatocellular carcinoma patients, but detection accuracy is insufficient and GPC3 is also detected in healthy individuals leading to false positives
Solution Approach 1:
The patent applies local quality by requiring detection of full-length GPC3 with specific structural integrity. The antibody system is designed to recognize the complete GPC3 structure rather than fragmented peptides, ensuring that only intact full-length GPC3 is detected. This structural specificity eliminates detection of degraded or fragmented forms, thereby improving measurement precision while reducing false positives in healthy individuals.
Solution Approach 2:
The patent changes the detection parameter from fragmented peptide recognition to full-length GPC3 recognition. By using an antibody system that requires both N-terminal and C-terminal regions to be present and properly configured, the detection threshold is effectively raised to require complete structural integrity. This parameter change distinguishes full-length GPC3 (present in HCC) from fragmented forms or background signals, improving both accuracy and reliability.
2Adaptability or versatility
If fragmented GPC3 peptides are detected, then the detection system can identify GPC3 presence, but it cannot distinguish between full-length functional GPC3 and degraded fragments
Solution Approach 1:
The patent uses full-length GPC3 structure itself as an intermediary requirement for detection. The antibody system is designed so that both N-terminal and C-terminal recognition sites must be present and properly oriented, which serves as a built-in verification mechanism. This intermediary requirement ensures that only complete, structurally intact GPC3 molecules are detected, automatically excluding fragmented peptides from the detection results.
3Ease of manufacture
If a detection system uses antibodies against arbitrary GPC3 sites, then it can be developed more easily, but it cannot specifically identify full-length GPC3 structure
Solution Approach 1:
The patent applies segmentation by dividing the GPC3 detection requirement into two distinct antibody components: one recognizing the N-terminal region and another recognizing the C-terminal region. This segmented approach ensures that both terminal regions must be present for successful detection, providing structural verification of full-length GPC3. The segmented antibody system is more reliable than single-site antibodies while remaining feasible to develop using standard hybridoma techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves the accuracy of recurrence risk prediction for hepatocellular carcinoma patients, with high specificity and low false positives, as full-length GPC3 is rarely detected in healthy individuals, thereby enhancing diagnostic reliability.
Implementation Method 1
measuring concentration of GPC3 peptide recognized by both a first monoclonal antibody and a second monoclonal antibody in a blood sample of hepatocellular carcinoma patient, using the first monoclonal antibody that recognizes a peptide having an amino acid sequence in the N-terminal side of GPC3 and the second monoclonal antibody that recognizes a peptide having an amino acid sequence in the C-terminal side of GPC3
Data Source
Figure 1~2
Figure 3
Figure 4A
AI summary
The present invention relates to a method, an apparatus, a computer program product and a kit for assisting recurrence risk prediction for hepatocellular carcinoma patients.